---
title: "Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295933699.md"
description: "A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions."
datetime: "2026-08-14T12:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295933699.md)
  - [en](https://longbridge.com/en/news/295933699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295933699.md)
generator: "portal-rs"
---

# Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUs](https://longbridge.com/en/news/296394220.md)
- [Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million](https://longbridge.com/en/news/295931365.md)
- [Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL](https://longbridge.com/en/news/296198190.md)
- [16:20 ETRobbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action](https://longbridge.com/en/news/296649920.md)
- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**